Which statement about RAAS blockade in CKD management is correct?

• A. RAAS Blockade Is Optional
• B. RAAS Blockade Is Foundational But Potassium And Creatinine Should Be Monitored
• C. RAAS Blockade Should Be Avoided In CKD
• D. RAAS Blockade Has No Effect On Blood Pressure

Answer: (B)

RAAS blockade is a foundation of CKD management because ACE inhibitors and ARBs protect kidney function and improve cardiovascular outcomes. They reduce intraglomerular pressure, decrease proteinuria, slow the decline of kidney function, and help control blood pressure, which is a key driver of CKD progression and heart disease risk. Because of their effect on the kidneys and on potassium handling, they must be used with careful labs: baseline creatinine and potassium, then close monitoring after starting or increasing the dose. A rise in creatinine can indicate hemodynamic changes in the kidney or early AKI, and higher potassium levels can lead to dangerous hyperkalemia. Therefore, checking potassium and creatinine in the short term (often within 1–2 weeks) and periodically thereafter is essential to adjust therapy safely. While RAAS blockade typically lowers blood pressure and provides kidney protection, it is not optional, and it does affect BP, so monitoring helps balance benefits with potential risks.